Ilorasertib
As of the edition of 20 October 2026, Ilorasertib is a small molecule: stopped in 2022; acts on AURKA, AURKB and AURKC and 15 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2022
- Kind
- Small molecule
- Registered trials
- 4, 1 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| AURKA | Aurora kinase A | O14965 |
| LCK | Tyrosine-protein kinase Lck | P06239 |
| FYN | Tyrosine-protein kinase Fyn | P06241 |
| YES1 | Tyrosine-protein kinase Yes | P07947 |
| LYN | Tyrosine-protein kinase Lyn | P07948 |
| HCK | Tyrosine-protein kinase HCK | P08631 |
| PDGFRB | Platelet-derived growth factor receptor beta | P09619 |
| FGR | Tyrosine-protein kinase Fgr | P09769 |
| SRC | Proto-oncogene tyrosine-protein kinase Src | P12931 |
| PDGFRA | Platelet-derived growth factor receptor alpha | P16234 |
| FLT1 | Vascular endothelial growth factor receptor 1 | P17948 |
| FLT4 | Vascular endothelial growth factor receptor 3 | P35916 |
| KDR | Vascular endothelial growth factor receptor 2 | P35968 |
| FRK | Tyrosine-protein kinase FRK | P42685 |
| BLK | Tyrosine-protein kinase Blk | P51451 |
| AURKB | Aurora kinase B | Q96GD4 |
| SRMS | Tyrosine-protein kinase Srms | Q9H3Y6 |
| AURKC | Aurora kinase C | Q9UQB9 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 1 | 0 | 0 | 1 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AbbVie | Lead sponsor of trials | 2010 to now |